Resumen de acción BHC Bausch Health Companies Inc. opera como empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Bausch Health Companies Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Bausch Health Companies Precios históricos de las acciones Precio actual de la acción US$7.53 Máximo en las últimas 52 semanas US$11.46 Mínimo de 52 semanas US$3.96 Beta 0.69 Cambio en 1 mes -5.52% Variación en 3 meses -6.23% Cambio de 1 año -1.70% Variación en 3 años -73.28% Variación en 5 años -74.83% Variación desde la OPV 1,406.00%
Noticias y actualizaciones recientes
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors Dec 03
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Price target increased by 7.1% to US$8.57 Nov 03
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01 Ver más actualizaciones
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors Dec 03
Bausch Health Companies Inc. Appoints Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D Dec 02
Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada Nov 19
Price target increased by 7.1% to US$8.57 Nov 03
Forecast breakeven date pushed back to 2025 Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA Oct 28
There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise Oct 10
Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 10
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely Sep 19
Price target decreased by 18% to US$7.79 Sep 14
Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel Sep 11
Executive VP & General Counsel exercised options and sold US$318k worth of stock Sep 10
Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28% Aug 06
Price target decreased by 11% to US$8.36 Aug 04
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024 Aug 01
2 Red Alerts On Bausch Health Companies Jul 25 Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma
Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 12
Price target decreased by 7.7% to US$9.56 Jul 10
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25% May 21
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 May 18
Bausch Health Companies Inc. Approves Directorate Appointments May 16
Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results May 07
First quarter 2024 earnings: EPS misses analyst expectations May 03
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan Apr 13
Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 12
Price target increased by 10% to US$10.33 Apr 05
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults Apr 03
Insufficient new directors Apr 01
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma Mar 06
Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation Feb 24
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 23
Consensus EPS estimates fall from profit to US$0.03 loss Feb 22
Bausch Health Companies Inc., Annual General Meeting, May 14, 2024 Feb 21 Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024
Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel Jan 31
Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Jan 09
Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis Dec 22
Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan Dec 19
Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Nov 30
Consensus EPS estimates fall by 89%, revenue upgraded Nov 09
New major risk - Negative shareholders equity Nov 07
No longer forecast to breakeven Nov 07
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 02
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet? Nov 01
FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older Oct 21
Consensus EPS estimates fall by 31% Oct 15
Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13
Consensus EPS estimates fall from profit to US$0.49 loss Oct 01
Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics Sep 24
Price target increased by 11% to US$9.50 Sep 20 Bausch Health Companies Inc. Announces Executive Changes
Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults Sep 14
Executive VP & CFO exercised options to buy US$1.1m worth of stock. Sep 10
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 08
Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc Sep 06
Consensus EPS estimates increase from loss to US$0.11 profit Aug 10
Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023 Aug 04
Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022) Aug 04
Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc Jul 27
Is Bausch Health Companies (NYSE:BHC) A Risky Investment? Jul 24
Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes Jul 06
New major risk - Financial position Jul 01
Consensus EPS estimates fall by 299% Jun 21
Price target decreased by 29% to US$8.50 Jun 17
What To Do After Bausch Health Stock Plunged By Nearly 9% Again Jun 07
Consensus EPS estimates upgraded to US$0.18 loss May 27
Price target decreased by 8.9% to US$11.92 May 19
Consensus EPS estimates upgraded to US$0.33 loss May 11
Forecast to breakeven in 2025 May 10
First quarter 2023 earnings: EPS misses analyst expectations May 06
Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023 May 05
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt Apr 18
Forecast breakeven date pushed back to 2025 Apr 18
CEO & Director exercised options to buy US$115k worth of stock. Mar 03
Price target increased by 8.3% to US$13.00 Feb 24
Full year 2022 earnings: EPS misses analyst expectations Feb 24
Investor sentiment improves as stock rises 24% Feb 16
Consensus EPS estimates increase by 214% Feb 03
Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Consensus EPS estimates increase by 214% Jan 29
Investor sentiment improved over the past week Jan 06
Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out Dec 30
Bausch Health Companies Inc. Announces Availability of ARAZLOTM Dec 23
Investor sentiment deteriorated over the past week Dec 22
Bausch Health acne lotion Arazlo available in Canada under public drug plans Dec 22
Bausch Health: Things To Consider Before Investing Dec 11
Consensus forecasts updated Nov 25
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues Nov 10
Third quarter 2022 earnings: EPS exceeds analyst expectations Nov 04
Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022 Nov 04
Bausch Health Companies Q3 2022 Earnings Preview Nov 02
Consensus forecasts updated Oct 29 Rentabilidad de los accionistas BHC US Pharmaceuticals Mercado US 7D -2.0% 0.6% -0.4% 1Y -1.7% 10.0% 24.8%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Los resultados de BHC fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 10% el año pasado.
Rentabilidad vs. Mercado: BHC obtuvo unos resultados inferiores a los del mercado US, que fueron del 24.8% el año pasado.
Volatilidad de los precios Is BHC's price volatile compared to industry and market? BHC volatility BHC Average Weekly Movement 6.7% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Precio estable de las acciones: BHC no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BHC (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Bausch Health Companies Inc. opera como una empresa diversificada de especialidades farmacéuticas y dispositivos médicos en Estados Unidos y a escala internacional. Desarrolla, fabrica y comercializa una gama de productos principalmente en gastroenterología, hepatología, neurología, dermatología, productos farmacéuticos internacionales, productos de venta libre (OTC), dispositivos médicos estéticos y salud ocular. La empresa opera a través de cinco segmentos: Salix, Internacional, Solta Medical, Diversified y Bausch + Lomb.
Mostrar más Resumen de fundamentos de Bausch Health Companies Inc. ¿Cómo se comparan los beneficios e ingresos de Bausch Health Companies con su capitalización de mercado? Estadísticas fundamentales de BHC Capitalización bursátil US$2.77b Beneficios(TTM ) -US$178.00m Ingresos (TTM ) US$9.47b
0.3x Ratio precio-ventas (PS)
-15.6x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de BHC Ingresos US$9.47b Coste de los ingresos US$2.76b Beneficio bruto US$6.71b Otros gastos US$6.89b Beneficios -US$178.00m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.48 Margen bruto 70.87% Margen de beneficio neto -1.88% Ratio deuda/patrimonio -8,887.2%
¿Cómo se ha desempeñado BHC a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/24 05:11 Precio de las acciones al final del día 2024/12/24 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Bausch Health Companies Inc. está cubierta por 46 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Raghuram Selvaraju Aegis Capital Corporation Douglas Tsao Barclays Ardalan Arfaei BMO Capital Markets Equity Research
Mostrar 43 más analistas 
